Pulmonary Drug Delivery of Antimicrobials and Anticancer Drugs Using Solid Dispersions

Pharmaceutics. 2021 Jul 10;13(7):1056. doi: 10.3390/pharmaceutics13071056.

Abstract

It is well established that currently available inhaled drug formulations are associated with extremely low lung deposition. Currently available technologies alleviate this low deposition problem via mixing the drug with inert larger particles, such as lactose monohydrate. Those inert particles are retained in the inhalation device or impacted in the throat and swallowed, allowing the smaller drug particles to continue their journey towards the lungs. While this seems like a practical approach, in some formulations, the ratio between the carrier to drug particles can be as much as 30 to 1. This limitation becomes more critical when treating lung conditions that inherently require large doses of the drug, such as antibiotics and antivirals that treat lung infections and anticancer drugs. The focus of this review article is to review the recent advancements in carrier free technologies that are based on coamorphous solid dispersions and cocrystals that can improve flow properties, and help with delivering larger doses of the drug to the lungs.

Keywords: coamorphous; cocrystals; dry powder inhalers; pulmonary drug delivery; solubility.

Publication types

  • Review